Reports have demonstrated that elevated APOC1 gene expression is significantly associated with the risk of T2D and TG levels; also, apoC1 glycosylation has been observed in patients with T2D, which impairs the ability of APOC1 to inhibit plasma cholesteryl ester transporter protein activity, suggesting that elevated apoC1 expression may increase the risk of T2D through lipoprotein metabolic pathways (71, 72). Here, APOC1 is linked to type 2 diabetes mellitus.